论文部分内容阅读
目的 nm23H1基因在卵巢癌中的表达情况及其临床意义。方法 选取 65例手术切除卵巢癌标本、卵巢良性肿瘤 30例和正常卵巢组织 29例, 常规 10%福尔马林固定, 石蜡包埋, 连续切片, 以针对nm23H1单克隆抗体, 行SABC免疫组化染色, 观察其在卵巢癌、良性卵巢肿瘤及正常卵巢组织的表达并分析相关的临床病理因素。结果 1. nm23H1阳性率在临床Ⅱ-Ⅳ期显著低于临床Ⅰ期、癌转移灶中显著低于原发灶、癌患者生存期小于 5年者显著低于生存期大于 5年者, P值均<0. 05; nm23H1阳性率在卵巢癌中亦显著高于良性瘤、正常卵巢组; 2. 残留灶≤2cm的nm23H1阳性率高于残留灶 >2cm的, 其差异有显著性 (P<0. 05);3. 本文资料中, 未看出nm23H1表达在卵巢癌患者不同年龄组、不同组织类型及病理分级间其阳性率有明显差异。结论 nm23H1在肿瘤早期、原发癌表达明显高于晚期、转移癌的事实与nm23H1转移抑制基因的功能相符合; 但其在恶性瘤中比良性瘤、正常卵巢组织中阳性率高的结果, 可能是机体遏制肿瘤、过度代偿的现象。故nm23H1基因产物可作为预测肿瘤转移潜能、评估预后的指标。
Objective To investigate the expression of nm23H1 gene in ovarian cancer and its clinical significance. Methods Totally 65 cases of ovarian cancer specimens, 30 cases of ovarian benign tumors and 29 cases of normal ovarian tissues were selected. The specimens were fixed in 10% formalin and paraffin-embedded, and were serially sectioned for nm23H1 monoclonal antibody. SABC immunohistochemistry Staining, observe its expression in ovarian cancer, benign ovarian tumor and normal ovarian tissue and analyze the related clinicopathological factors. The positive rate of nm23H1 in clinical stage Ⅱ-Ⅳ was significantly lower than that in clinical stage Ⅰ, the metastasis of cancer was significantly lower than that of primary tumor. The survival rate of patients with cancer less than 5 years was significantly lower than those with survival of more than 5 years The positive rate of nm23H1 in ovarian cancer was also significantly higher than that in benign and normal ovarian groups.2.The positive rate of nm23H1 in residual lesions ≤2cm was higher than that in residual lesions> 2cm (P < 0.05) .3. In this paper, nm23H1 expression was not observed in ovarian cancer patients of different age groups, the different types of tissues and pathological grading between the positive rates were significantly different. Conclusion The expression of nm23H1 in early stage of primary tumor is significantly higher than that in advanced stage. The fact of nm23H1 metastasis is consistent with the function of nm23H1 metastasis suppressor gene. However, the positive rate of nm23H1 in benign tumor and normal ovary tissue may be higher Is the body to stop the tumor, over-compensated phenomenon. Therefore, the nm23H1 gene product can be used as a predictor of tumor metastasis potential, an indicator of prognosis.